Immediate Impact
28 standout
Citing Papers
Cystic fibrosis
2024 Standout
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
2023 Standout
Works of Karsten Kötz being referenced
Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Karsten Kötz | 88 | 68 | 43 | 64 | 8 | 160 | |
| S Scoccia | 71 | 63 | 25 | 104 | 12 | 216 | |
| Parisa Sabbagh | 37 | 40 | 112 | 43 | 8 | 213 | |
| Ian D. Jones | 18 | 55 | 42 | 69 | 11 | 177 | |
| Tomasz M. Ziedalski | 69 | 34 | 41 | 67 | 9 | 189 | |
| Hiroyuki Kokuto | 128 | 112 | 41 | 19 | 8 | 178 | |
| Amanda Lopes | 104 | 33 | 19 | 9 | 13 | 152 | |
| Atsuya Narita | 78 | 76 | 23 | 17 | 9 | 145 | |
| Gema Fernández | 74 | 18 | 34 | 86 | 10 | 191 | |
| Pangestu Adi | 85 | 13 | 143 | 43 | 11 | 233 | |
| Oveimar De La Cruz | 85 | 51 | 17 | 25 | 10 | 126 |
All Works
Login with ORCID to disown or claim papers
Loading papers...